SCHEMBL13080488

SCHEMBL13080488

CCOC(=O)c1cn(C2CCN(C)C2)c2ccc(I)cc2c1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.45
LMNA P02545 1/20 0.44
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
MAPT P10636 1/20 0.43
THRB P10828 1/20 0.43
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
HSD17B10 Q99714 2/20 0.40
GAPDH P04406 1/20 0.40
MAP2K2 P36507 1/20 0.39
MAP2K1 Q02750 1/20 0.39
CNR1 P21554 1/20 0.38
CNR2 P34972 1/20 0.38
ADRB2 P07550 1/20 0.38
HTR6 P50406 1/20 0.38
PTPN1 P18031 1/20 0.38
GAA P10253 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13080528 1.00 HPGD (0.45) HPGDLMNAKMT2AMEN1MAPT
SCHEMBL2999615 0.94 HPGD (0.44) HPGDLMNAKMT2AMEN1MAPT
SCHEMBL2995842 0.94 HPGD (0.46) HPGDLMNAKMT2AMEN1MAPT
SCHEMBL3004714 0.92 LMNA (0.47) HPGDLMNAKMT2AMEN1MAPT
SCHEMBL13080490 0.89 HPGD (0.47) HPGDLMNAKMT2AMEN1MAPT
SCHEMBL3004100 0.89 LMNA (0.50) HPGDLMNAKMT2AMEN1MAPT
SCHEMBL3005757 0.86 KDM4E (0.48) HPGDLMNAKMT2AMEN1MAPT
SCHEMBL13080493 0.86 HPGD (0.45) HPGDLMNAKMT2AMEN1MAPT
SCHEMBL1430148 0.86 KDM4E (0.47) HPGDLMNAMAPTKDM4EALDH1A1
SCHEMBL27813125 0.86 KDM4E (0.47) HPGDLMNAMAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8283361-B2 Heterocyclic urea derivatives and methods of use thereof ASTRAZENECA AB (SE) 2012-10-09 US disclosed
US-20100190745-A1 HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-07-29 US disclosed
US-20100190745-A1 HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-07-29 US disclosed
WO-2009147433-A1 HETEROCYCLIC UREA DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS ASTRAZENECA AB (SE) 2009-12-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190745-A1 HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF UROD, UMPS, SLC14A1 HPGD 137/4885LMNA 2705/4885KMT2A 3820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.